University spinout announces positive results from peptide therapeutic trial for patients with relapsing Multiple Sclerosis (MS)
A University of Bristol spinout company that focuses on treating the underlying cause of autoimmune diseases has announced positive results from its peptide therapeutic trial for patients with relapsing Multiple Sclerosis (MS).









